18
Participants
Start Date
August 31, 2018
Primary Completion Date
February 17, 2020
Study Completion Date
February 17, 2020
Alirocumab SAR236553 (REGN727)
"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
Atorvastatin
"Pharmaceutical form: tablet,~Route of administration: oral"
Simvastatin
"Pharmaceutical form: tablet,~Route of administration: oral"
Fluvastatin
"Pharmaceutical form: capsule,~Route of administration: oral"
Pravastatin
"Pharmaceutical form: tablet,~Route of administration: oral"
Lovastatin
"Pharmaceutical form: tablet,~Route of administration: oral"
Rosuvastatin
"Pharmaceutical form: tablet,~Route of administration: oral"
Ezetimibe
"Pharmaceutical form: tablet,~Route of administration: oral"
Cholestyramine
"Pharmaceutical form: oral suspension,~Route of administration: oral"
Nicotinic acid
"Pharmaceutical form: tablet,~Route of administration: oral"
Fenofibrate
"Pharmaceutical form: tablet,~Route of administration: oral"
Omega-3 fatty acids
"Pharmaceutical form: capsule,~Route of administration: oral"
Investigational Site Number 1580001, Taipei
Investigational Site Number 7050001, Ljubljana
Investigational Site Number 2080001, Viborg
Investigational Site Number 7240001, A Coruña
Investigational Site Number 7920001, Izmir
Investigational Site Number 4840006, Oaxaca City
Investigational Site Number 6430002, Kemerovo
Investigational Site Number 0760001, São Paulo
Investigational Site Number 1240001, Québec
Investigational Site Number 5280001, Amsterdam
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY